PuraPharm Corporation Limited announced unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months, the company reported revenue of HKD 212.249 million against 186.902 million a year ago. Profit before tax was HKD 10.386 million against loss before tax of HKD 5.241 million a year ago. Profit for the period was HKD 8.285 million against loss of HKD 7.596 million a year ago. Profit attributable to owners of the parent was HKD 8.285 million against loss attributable to owners of the parent of HKD 7.596 million a year ago. Basic and diluted earnings per share attributable to ordinary equity holders of the parent was 3.7 cents against basic and diluted loss per share attributable to ordinary equity holders of the parent of 4.5 cents a year ago. The group's revenue for the six months ended 30 June 2016 was increased HKD 25.3 million or 13.6% compared to the corresponding period of last year. The revenue growth was mainly attributable to the moderate growth of the Group's CCMG products in both Mainland China and Hong Kong market, and fast expansion of the Group's Nong's® Chinese medicine clinics in Hong Kong. The group's capital expenditures primarily comprised of payments and deposits for purchase of property, plant and equipment, land use rights and intangible assets. During the six months ended 30 June 2016, the total capital expenditure was HKD 35.1 million, compared with HKD 31.6 million for the six months ended 30 June 2015. The capital expenditures during the period under review were mainly incurred for acquisition of production equipment and enhancement of existing production line, and also acquisition of intellectual properties in respect of the two Chinese medicines management software for clinic operation.